Coronavirus BRIEFING
Supported by Essilor

The Latest COVID-19 Data

The National Average for Gross Revenue at ECP Locations Remained Flat for the Week of November 4–10, Jobson’s Latest Practice Performance Tracker Shows

By Staff
Friday, November 15, 2024 12:27 AM NEW YORK—The national average for gross revenue at ECP locations remained flat last week, November 4–10, when compared with the previous week. That places gross revenue at a level 17 index points above where it was at this point in time (Week 45) when compared with last year (2023), 18 points above the same period in 2022, 28 points above 2021, 21 points above 2020 and 28 points above 2019, according to Jobson’s most recent Practice Performance Tracker.

The National Average for Gross Revenue at ECP Locations Increased for the Week of October 28–November 3, Jobson’s Latest Practice Performance Tracker Shows

By Staff
Thursday, November 7, 2024 12:15 AM NEW YORK—The national average for gross revenue at ECP locations increased last week, October 28–November 3, when compared with the previous week, at a rate of 3 index points. That places gross revenue at a level 16 index points above where it was at this point in time (Week 44) when compared with last year (2023), 20 points above the same period in 2022, 27 points above 2021, 24 points above 2020 and 33 points above 2019, according to Jobson’s most recent Practice Performance Tracker.

5 Decisions That Dramatically Cut Your Stress

By Staff
Wednesday, November 6, 2024 7:59 AM

What Trump Has Proposed for Health Care in a Second Administration

By Staff
Wednesday, November 6, 2024 6:09 AM Donald Trump has promised sweeping action in a second administration. The former president and now president-elect often skipped over details but through more than a year of policy pronouncements and written statements outlined a wide-ranging agenda.

Year in Review: A Look Back at Newsworthy COVID-19 Stories of 2024

By Staff
Tuesday, November 5, 2024 6:09 AM This year's headlines on COVID-19 featured new research on COVID-related mortality, post-acute sequelae of infection, vaccine safety and potential therapeutics.

Public Health Department Barred From Giving COVID Vaccine

By Staff
Monday, November 4, 2024 6:09 AM A regional public health department in Idaho is no longer providing COVID-19 vaccines to residents in six counties after a narrow decision by its board.

COVID on the Floor Linked to Outbreaks on Two Hospital Wards

By Staff
Friday, November 1, 2024 8:05 AM The viral burden of SARS-CoV-2 on floors, even in health care worker–only areas, was strongly associated with COVID-19 outbreaks in two acute-care hospitals, according to a new study from Ontario, Canada.

You May Not Need to Throw Out Those ‘Expired’ Covid-19 Home Tests

By Staff
Friday, November 1, 2024 6:09 AM Four free home Covid-19 antigen tests are available to order at COVIDTests.gov, part of the seventh round of the federal government’s test-distribution program.

The National Average for Gross Revenue at ECP Locations Remained Flat for the Week of October 21–27, Jobson’s Latest Practice Performance Tracker Shows

By Staff
Friday, November 1, 2024 12:24 AM NEW YORK—The national average for gross revenue at ECP locations remained flat last week, October 21–27, when compared with the previous week. That places gross revenue at a level 13 index points above where it was at this point in time (Week 43) when compared with last year (2023), 16 points above the same period in 2022, 24 points above 2021, 20 points above 2020 and 32 points above 2019, according to Jobson’s most recent Practice Performance Tracker.

Low COVID and Flu Vaccine Uptake Among Risk Groups in Europe

By Staff
Thursday, October 31, 2024 8:05 AM Uptake of seasonal influenza and COVID-19 vaccination among risk groups such as older adults in many European Union/European Economic Area member states between 2023 and 2024 has been suboptimal, according to two reports released by the European Centre for Disease Prevention and Control.

What It Will Take to Get a Next-Generation COVID Vaccine

By Staff
Wednesday, October 30, 2024 8:05 AM Nearly 4 years since the first messenger RNA (mRNA) COVID-19 vaccines were developed, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus is evolving more quickly than tailored boosters can be made ready and continues to kill hundreds of Americans every week. There is a pressing need for more durable and lasting protection, but there is no “Operation Warp Speed” working to create new and better vaccines, only pandemic fatigue, experts said.

Japan's Shionogi Says Phase 3 Study Showed COVID Pill Reduces Transmission

By Staff
Tuesday, October 29, 2024 8:05 AM Japan's Shionogi & Co said on Tuesday a global, late-stage study showed its pill-based treatment for COVID-19 was effective in reducing transmission of the disease.

Obesity May Raise Risk of Long COVID in Youth

By Staff
Tuesday, October 29, 2024 6:09 AM Elevated body mass index (BMI) in children and young adults was associated with an increased risk of post-acute sequelae of SARS-CoV-2 infection (PASC), or long COVID, a large retrospective cohort study suggested.

The National Average for Gross Revenue at ECP Locations Remained Flat for the Week of October 14-20, Jobson’s Latest Practice Performance Tracker Shows

By Staff
Friday, October 25, 2024 12:24 AM NEW YORK—The national average for gross revenue at ECP locations remained flat last week, October 14-20, when compared with the previous week. That places gross revenue at a level 18 index points above where it was at this point in time (Week 42) when compared with last year (2023), 18 points above the same period in 2022, 29 points above 2021, 21 points above 2020 and 30 points above 2019, according to Jobson’s most recent Practice Performance Tracker.

New Flu and Updated COVID Vaccines Greenlighted by Europe

By Staff
Thursday, October 24, 2024 8:05 AM Europe's Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization for two vaccines: Fluad (surface antigen, inactivated, adjuvanted) and Flucelvax (surface antigen, inactivated, prepared in cell cultures) for active immunization against influenza. The CHMP also recommended a revised composition for Nuvaxovid, an already approved vaccine that targets the JN.1 variant of the SARS-CoV-2 virus.